bluebird bio (BLUE) Shares are Down -5.44%

bluebird bio (BLUE) has risen sharply, recording gains of 38.19% in the past 4 weeks. However, the stock has corrected -5.44% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 38.93% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.11% and the 50-Day Moving Average is 16.89%.The 200 Day SMA reached 36.02%


bluebird bio (NASDAQ:BLUE): After opening at $67.05, the stock dipped to an intraday low of $65.68 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $68.85 and the buying power remained strong till the end. The stock closed at $67.78 for the day, a gain of 2.06% for the day session. The total traded volume was 1,149,692. The stocks close on the previous trading day was $67.78.

bluebird bio (BLUE) : The consensus price target for bluebird bio (BLUE) is $85.25 for the short term with a standard deviation of $25.18. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $120, however, the pessimist price target for the company is $42.

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *